‘Although the toxic beta amyloid peptide was initially isolated from the mind arteries of Alzheimer’s patients, the contribution of pathological adjustments in brain vascular cells to the disease has not been well studied,’ says Dave R. Schubert, Ph.D., professor and head of the Cellular Neurobiology Laboratory. ‘Our data clearly describe a biochemical mechanism to explain the epidemiology, and identify targets for drug development.’ Alzheimer’s and diabetes are two diseases that are raising at an alarming price within the U.S. People. Alzheimer’s impacts one in 10 Americans over 65 years and nearly 50 % of those over 85 years aged.‘CL-H1T contains a known medication for migraine headaches with formulated promethazine specially, a secure and efficient anti-emetic medication,’ Dr. Schachtel stated. ‘This Phase I study will determine the bioavailability of both substances in this new mixture treatment.’ ‘This announcement can be another exemplory case of the depth of our technology pipeline and our overall commitment to research and development in the area of pain administration,’ said Mr. Paul Bosse, President and Chief Executive Officer at Charleston Laboratories, Inc. ‘We anticipate getting this product to physicians and their migraine individuals who want the dual therapy that CL-H1T provides.’ Charleston Laboratories currently has a advancement and commercialization partner, Daiichi Sankyo, Inc., for its first product, CL-108, which is completing Stage 3 clinical trials.
Arizona resident receives donor center transplant after coping with SynCardia Total Artificial Heart Randy Shepherd, an Arizona resident nicknamed the ‘tin man,’ has received a donor heart transplant after 15 weeks of support from the SynCardia temporary Total Artificial Heart.